a Aripiprazole blocks psychostimulant seeking in a rat model of relapse. However, in humans, it may increase ongoing use. We tested aripiprazole specifically for relapse prevention. Methadone-maintained outpatients who were abstinent from cocaine in weeks 11-12 were randomized to double-blind aripiprazole (15 mg daily) or placebo in weeks 13-27 after 12 weeks of contingency management. Participants reported craving through ecological momentary assessment. We stopped the trial because very few (18/41) participants fulfilled the abstinence criterion. The results suggested that aripiprazole delayed lapse [hazard ratio (HR) = 0.45, 95% confidence interval (CI) = 0.14-1.42, P = 0.17] and relapse (HR = 0.31, 95% CI = 0.07-1.27, P = 0.10), but the effects did not reach statistical significance. Unexpectedly, the proportion of participants reporting cocaine craving was higher in the aripiprazole group (Fisher's exact P = 0.026), although the frequency of craving was similar in the aripiprazole and placebo groups (1.89 vs. 1.16%, r effect = 0.43, 95% CI = − 0.08 − 0.76). The results suggest that in recently abstinent cocaine users, aripiprazole might delay relapse, but might also slightly increase craving. Difficulty in trial implementation underscores the fact that initial abstinence from cocaine is not a trivial hurdle. Behavioural Pharmacology 28:63-73
Introduction
A major problem in treating substance-use disorders is the likelihood of relapse, which can occur after seemingly successful abstinence, with an array of precipitants that often include drug-associated environmental cues (Brandon et al., 2007) . In the rat reinstatement model of relapse and craving, resumption of extinguished cocaine seeking by either of two types of precipitants (cues and small priming doses of cocaine) was reduced by aripiprazole (Shaham et al., 2003; Feltenstein et al., 2007 Feltenstein et al., , 2009 . Aripiprazole is a partial agonist at dopamine D 2 and serotonin 5-HT 1A receptors and an antagonist at 5-HT 2A receptors with affinity for several other dopaminergic, serotonergic, adrenergic, and histaminergic receptors (Davies et al., 2004) . It is used clinically for the treatment of schizophrenia, manic or mixed episodes associated with bipolar I disorder, or as adjunctive treatment for major depressive disorder in adults. The effect of aripiprazole in the rat model of relapse was specific, with no accompanying changes in cocaine selfadministration, food self-administration, reinstatement of food-seeking behavior, or basal locomotor activity (Feltenstein et al., 2007) . The effect persisted when aripiprazole was administered every day for 1 week (Feltenstein et al., 2009) . The clinical implication of these findings is that aripiprazole might prevent cue-induced relapse in addicted cocaine users who have become abstinent.
Relapse prevention has not been an outcome measure in the extant human literature on aripiprazole for psychostimulant addiction. This might help explain some seemingly conflicting results. One group of investigators has consistently found beneficial effects of acutely administered aripiprazole in non-treatment-seeking misusers of D-amphetamine or methamphetamine: acute aripiprazole reduced amphetamine's discriminative-stimulus effects (Lile et al., 2005) , positive subjective effects (Stoops et al., 2006) , and rates of self-administration (Stoops et al., 2013) . Yet, when administered chronically to nontreatment-seekers with psychostimulant dependence, aripiprazole increased amphetamine use (Tiihonen et al., 2007) , increased positive subjective effects of cocaine (Lile et al., 2008) , and increased self-administration of cocaine (although this may have been a compensatory response to blunted reward) (Haney et al., 2011) . In the most recently published study, chronic aripiprazole had no effect on cocaine self-administration or subjective effects; again, the participants were non-treatmentseeking users (Lofwall et al., 2014) . A meta-analysis concluded that antipsychotics, including aripiprazole, have no effects relative to placebo in terms of cocaine-use days, cocaine or amphetamine/methamphetamine abstinence or craving, or severity of addiction in patients with psychostimulant dependence (Kishi et al., 2013 ).
Yet, none of these findings address the implications of the reinstatement results. Aripiprazole maintenance might be useful for relapse prevention in abstinent former users of cocaine -even though, as human studies and other rat models (Thomsen et al., 2008) suggest, it might actually exacerbate ongoing use in people who have not become abstinent. We designed a clinical trial with this difference in mind, randomizing only participants who achieved 2 weeks of initial abstinence. Because the reinstatement model is considered a model of both craving and relapse, we hypothesized that (i) aripiprazole would prevent or delay cocaine relapse more effectively than placebo and (ii) aripiprazole would reduce cocaine craving in daily life, as assessed by ecological momentary assessment (EMA). The design of this trial was almost identical to that of our successful, concurrently run trial of clonidine as an adjuvant to buprenorphine maintenance for opiate relapse prevention (Kowalczyk et al., 2015) . The results, as we will discuss, were different.
Methods

Study design
We conducted a randomized double-blind clinical trial with two treatment groups: aripiprazole (15 mg oral daily) and placebo. Figure 1 shows the timeline for the study. All patients received standard treatment (methadone daily and individual counseling weekly) for 41 weeks. To establish abstinence before aripiprazole induction, contingent vouchers were given for each cocaine-negative urine specimen during the first 12 weeks (weeks 1-12). Participants who were abstinent from cocaine during weeks 11 and 12 were randomized to receive aripiprazole or placebo in weeks 13 through 27 (induction with gradual dose escalation, as described below, weeks 13 and 14; intervention, weeks 15-26; and taper, week 27) . All participants continued to receive standard individual counseling and were maintained on their stabilization dose of methadone. After the maintenance phase, participants' methadone dosages were tapered over another 8 weeks or participants were assisted in transferring to another treatment program.
The primary outcome measures were time to lapse and relapse and longest duration of cocaine abstinence during intervention. The proportion of drug-negative urine specimens was also evaluated as a secondary measure. In addition, drug use, drug craving, and mood were assessed through EMA.
Participants
Participants were cocaine-using, opioid-dependent outpatient volunteers who were seeking treatment for both cocaine and opioid use, recruited from July 2009 to June 2012. Study candidates were evaluated with standardized interviews, physical examination, and laboratory screening. Inclusion criteria were physical dependence on opioids, current cocaine use on at least 3 of the last 30 days, lifetime cocaine-use duration of at least 1 year, seeking treatment for opiate and cocaine use, able to attend methadone clinic 7 days/week, and age between 18 and 60 years. The exclusion criteria were as follows: any medical illness that would compromise participation; self-reported intolerance to either methadone or aripiprazole; severe immunocompromise; pregnancy or breastfeeding; orthostatic hypotension; marked, sustained high blood pressure; ECG abnormalities; contraindicated medications; and cognitive impairment, schizophrenia, or any other DSM-IV psychotic disorder, bipolar disorder, major depressive disorder, previous suicide attempts or ideation, dementia, current physical dependence on alcohol or sedative-hypnotics, or a BMI over 40. Upon beginning the study, patients were maintained on methadone treatment at our outpatient treatmentresearch clinic in Baltimore, beginning at 30 mg on day 1 and increasing over the next 14 days to a target dose of 100 mg. Further, methadone dose adjustment was individualized on the basis of opioid withdrawal symptoms, craving, and use. Throughout the study, including baseline, we encouraged participants to become abstinent from opioids, but we did not discharge participants for testing positive for opioids. Throughout the study, participants attended the clinic 7 days a week for methadone; once a week, they received a session of individual counseling. Participants provided urine and breath samples under observation three times a week. Urine specimens were tested for opioids, cocaine, marijuana, amphetamines, barbiturates, and benzodiazepines; breath samples were tested for alcohol.
The Institutional Review Board of the National Institute on Drug Abuse Intramural Research Program approved the study and all participants provided written informed consent.
Baseline/cocaine abstinence initiation
Participants were told repeatedly -during intake, during consent, and weekly during the baseline -that they must become abstinent from cocaine by the end of their 10th week in the study and remain abstinent for the next 2 weeks (weeks 11 and 12) to qualify for continued participation. During the first 14 weeks of the study, we attempted to facilitate cocaine abstinence by using contingency management. All participants could earn vouchers (exchangeable for goods and services) for cocaine-negative urine specimens; the value of the vouchers began at $2 and increased in value by $2 for each consecutive negative specimen, to a maximum of $40. If a participant provided a cocaine-positive specimen or did not provide a scheduled specimen, the participant did not receive a voucher and the value of the next earned voucher was reset to $2. On the second day of urine collection, in addition to earning a $2 voucher if they gave a cocaine-negative urine, the participant had the chance to receive another voucher of random value. The priming voucher ($8-$40) was chosen out of a hat and participants received a statement about how many consecutive cocaine-negative urine samples would be needed to obtain a voucher of that value.
Participants who were abstinent from cocaine during weeks 11 and 12 (verified by six consecutive cocainenegative urines) were randomized to aripiprazole or placebo by an investigator (K.L.P.) who had no contact with participants using a computerized algorithm stratified by age, sex, race, and baseline cocaine and opioid use. All other staff and participants were blinded to study group assignment. Participants who were randomized continued to undergo contingency management during a 2-week aripiprazole/placebo induction phase. Participants who did not fulfill the abstinence criterion were offered 12 additional weeks of treatment, including an 8-week medication taper, or were helped to transfer to a community treatment program.
Aripiprazole/placebo
Aripiprazole (Bristol-Meyers Squibb; New York, New York, USA) and placebo were administered in identical size 0 capsules filled with dextrose. Aripiprazole/placebo administration began at the start of week 13 for an induction period of 14 days, followed by a 12-week intervention period. One capsule containing aripiprazole or placebo was administered once daily at the time of methadone administration. Nurses performed a mouth search and asked participants to speak after administration of the capsule.
During the 2-week induction, participants received increasing oral doses of aripiprazole (or placebo) once daily, starting at 5 mg and incrementing in 5-mg steps as tolerated to a maximum dose of 15 mg. Doses were lowered by the study physician (K.A.P.) in a blinded manner as necessary if side effects emerged. A participant could have remained in the study even if the aripiprazole dose had been lowered to 0, although this did not occur. The maximum tolerated dose was administered until the end of the 12-week intervention period. The dose of aripiprazole was tapered to 0 in the first 7 days of the 7-week maintenance phase in 5 mg decrements. Participants on placebo continued to receive placebo during the 7-day taper period.
Aripiprazole is not currently approved by the Food and Drug Administration for use as a treatment for cocaine relapse or craving.
Ecological momentary assessment of craving and mood
Participants' self-reported craving and mood were assessed by EMA. Each participant was issued a device (e.g. PalmPilot; Palm Inc., Sunnyvale, California, USA) and trained in its use as an electronic diary. From the first week of intervention until the end of the maintenance phase (weeks 13-33), the electronic diary randomly prompted participants four times a day to make EMA entries. Participants answered stress, craving, and mood questions with the response options 'NO!!', 'no??', 'yes??', and 'YES!!' and reported whether drug cues were encountered in the hour before the prompt. Participants were also asked to initiate EMA entries whenever they used cocaine or had an urge/craving for cocaine.
Adverse events
Our nursing staff monitored adverse events by participant self-report, vital signs, ECG, liver-function tests, and fasting glucose. Research assistants monitored participants for extrapyramidal symptoms using a battery consisting of the Barnes Akathisia Scale (Barnes, 1989) , the Abnormal Involuntary Movement Scale (Guy, 1976) , and the Simpson-Angus Scale (Simpson and Angus, 1970) . Adverse events, including extrapyramidal symptoms, were further evaluated by the study physician as appropriate.
Data analysis
Group differences in proportions of cocaine-negative urine samples, and lengths of the longest periods of abstinence from cocaine, were analyzed using t-tests.
We defined lapse as the first cocaine-positive urine sample from week 13 to week 26. We defined relapse as two consecutive cocaine-positive urine samples or missed urines. Participants who dropped out (n = 4) were considered to have lapsed and relapsed. Those who remained abstinent until the end of the intervention phase were coded as right censored. Group differences in latency to lapse and relapse were analyzed using Cox proportional hazards models (using SAS Proc PHreg; SAS 9.4, SAS Institute Inc., Cary, North Carolina, USA); the assumption of proportional hazards across groups was met, except where indicated in the Results section.
There were four complications in the data analysis; we handled them as follows:
First, one participant randomized to the placebo group was providing urine specimens that were negative for methadone -a finding highly suggestive of falsification. This started on the day before randomization and continued for the first 2 weeks of placebo, at which point, clinic staff noticed it and asked him about it. He acknowledged that he had been using a commercial 'urine cleansing' product. He was discharged from the study (he transferred directly to a community methadone clinic). Rather than attempting to determine which of his data were reliable or whether he had even been eligible for randomization, we excluded his data from all analyses.
Second, our full intent-to-treat (ITT) sample (n = 18) included one participant in each group whose outcomes cannot plausibly be interpreted as intervention induced. One of them was randomized (to the aripiprazole group) on a Friday after 2 weeks of abstinence from cocaine, but lapsed to cocaine use over the weekend before receiving his first dose of aripiprazole on Monday (and continuing to use cocaine thereafter). The other was randomized to placebo, took one placebo capsule, and then transferred out of the study to a community clinic because of a schedule conflict (but therefore had to be counted as having immediately 'lapsed' and 'relapsed'). We report ITT results for lapse and relapse in this paper, and we report ITT results for other outcomes in the Appendix, but -for all results -we focus on an 'as-treated' analysis (n = 16) in which we do not include those two participants.
Third, the aripiprazole and placebo groups differed slightly on one relevant pre-enrollment measure, lifetime years of heroin use (more years in the participants randomized to aripiprazole; Table 1 ). We report our main results with and without years of heroin use as a covariate.
Finally, because our hypothesized group difference in lapse was not significant at a two-tailed α of 0.05, we used the hazard ratios (HRs) to calculate Bayes factors, thereby testing whether our data were inconclusive or whether they actually supported the null hypothesis of no benefit (Dienes, 2014) . Bayes factors greater than 3.0 suggest strong support for the alternative hypothesis over the null; Bayes factors less than 0.3 suggest strong support for the null; and values in between indicate that the data are insensitive or inconclusive (Dienes, 2014) . Bayes factors do not use investigator-specified estimates of previous probabilities; they simply test a null effect (e.g. no group difference) against an alternative hypothesized effect, which we took from the lapse results of our successful trial of clonidine maintenance for opiate users (Kowalczyk et al., 2015) . We specified a half-normal theorized distribution (see Dienes, 2014, for description) . For relapse, we did not calculate a Bayes factor because our clonidine study did not provide a basis for a theorized value.
EMA random-prompt data were analyzed using generalized linear mixed models (SAS Proc Glimmix; SAS 9.4, SAS Institute Inc.). The independent variable was treatment group; the dichotomous dependent variable was craving for cocaine ('yes??' or 'YES!!' coded 1; 'no??' or 'NO!!' coded 0). These models used a first-order 14.5 (6.9) 9.1 (9.9) t = 1.27, P = 0. autoregressive error structure and included a control term for the number of responses provided by each participant. We used similar general linear mixed models (SAS Proc Mix; SAS 9.4, SAS Institute Inc.) to compare groups on EMA ratings of stress and mood at random prompts. We did not analyze the self-initiated event-contingent prompts because, in this data set, those data were too sparse.
For all analyses, we used a two-tailed α of 0.05. Where appropriate, we used F values to calculate effect-size r values (r effect values) as specified by Rosnow et al. (2000) .
Results
We had planned to enroll 55 participants in each of the two groups. After enrollment of 41 participants, we ended the study because of slow recruitment and an unexpectedly low rate of initial cocaine abstinence in people who did enroll. Figure 2 shows the flow of participants through the study. As described below in the section on adverse events: out of nine participants randomized to receive aripiprazole, three received the maximum 15 mg dose as planned, five had the dose reduced to 5 mg for most of the intervention phase, and one discontinued aripiprazole after 3 weeks.
Demographics
Of the 41 participants enrolled, 18 (not counting the one who falsified his urine samples) fulfilled the cocaineabstinence criterion for randomization to aripiprazole or placebo; they constituted the ITT sample. Compared with the 22 who did not fulfill the cocaine-abstinence criterion, the 18 randomized participants were more likely to be men and tended to be older, more educated, more likely to be employed, and more likely to be African American (demographics for ITT sample and nonrandomized enrollees are shown in Appendix  Table A1 ).
Demographics for the 'as-treated' sample (n = 16) are shown in Table 1 . Among these 16, participants in the aripiprazole group were older than those in the placebo group and, as noted above, had more lifetime years of heroin use. We controlled for years of heroin use rather than age because years of heroin use was more closely related to outcome.
The two groups did not differ in the percentage of urine samples positive for cocaine or heroin during the 10 weeks of baseline treatment (data not shown); randomization had been stratified on those variables.
Lapse to cocaine use (assessed by urine screen) Lapse in 'as-treated' sample
The aripiprazole group appeared to take longer to lapse, with a HR of 0.45 (Fig. 3a) , but this HR was not significantly different from 1.0, with a 95% confidence interval (CI) of 0.14-1.42 (P = 0.17). To help determine whether the negative finding clearly indicated the absence of a treatment effect, we calculated a Bayes factor as prescribed in the appendix of Dienes (2014) using the natural log of the HR versus a theorized value. The observed HR had a natural log of − 0.8 (SEM = 0.58); our theorized natural log was − 0.39 (SD = 2.19), taken from the significant protective effect of clonidine in our previous study. (The use of SEM for one value and SD for the other accords with the published procedure.) The resultant Bayes factor was 1.19, suggesting that the result was inconclusive rather than strongly supportive of the null.
Using the same methods (Dienes, 2014) to compare the two HRs with each other directly, we found that they were not significantly different (z = 0.45, P = 0.65) -that is, we did not show that aripiprazole was less effective against cocaine lapse than clonidine had been against opiate lapse. This is consistent with the inconclusive Bayes factor.
Lapse in 'as-treated' sample, controlling for years of heroin use
Because aripiprazole participants tended to have longer histories of heroin use than placebo participants, we carried out a sensitivity analysis in which we included this as a covariate in our Cox models. (Years of heroin use did not meet the assumption of proportional hazards; thus, we also included its interaction with time.) Longer history of heroin use was associated with longer latency to lapse (HR = 0.89, 95% CI = 0.80-0.99, P < 0.05), but inclusion of the covariate did not appreciably change the aripiprazole/placebo comparison (HR = 0.32, 95% CI = 0.06-1.76, P = 0.19). The Bayes factor for this comparison of lapses was 1.49, again suggesting that the result for lapses was inconclusive.
Lapse in intent-to-treat sample
For the full sample, lapse results were similarly suggestive (Fig. 3b) , similarly nonsignificant (HR = 0.51, 95% CI = 0.18-1.48, P = 0.21), and similarly inconclusive (Bayes factor = 0.92). Covarying for years of heroin use did not change the findings appreciably (HR = 0.48, 95% CI = 0.11-2.19, P = 0.35, Bayes factor = 0.84).
Relapse to cocaine use (assessed by urine screen)
The group difference in time to relapse was, if anything, more pronounced than the group difference in time to lapse ( Fig. 4a and b ), but again, this did not reach statistical significance ('as-treated' sample, HR = 0.31, 95% CI = 0.07-1.27, P = 0.10; ITT sample, HR = 0.39, 95% CI = 0.11-1.37, P = 0.14). Years of heroin use as a sole predictor tended to predict longer latency to relapse ('astreated' sample, P = 0.09; ITT sample, P = 0.07); when we included years of heroin use as a covariate, the difference between the aripiprazole and placebo groups was slightly reduced (HR = 0.31, 95% CI = 0.04-2.08, P = 0.22). We did not calculate Bayes factors for relapse because our clonidine study did not provide a basis for a hypothesis.
Results from this point on are reported only for the 'astreated' sample; see the Appendix for more of the ITT results.
Longest duration of cocaine abstinence and overall proportions of negative urines
Findings were similarly suggestive for duration of cocaine abstinence, measured as the longest run of cocainenegative urine samples throughout the induction and intervention phase (weeks 13-26): aripiprazole did not increase it significantly (aripiprazole, M = 22.63, SEM = 4.73; placebo, M = 16.13, SEM = 4.54, P = 0.34), but the Bayes factor (using the relevant previous result from our clonidine study) was 1.67, again indicating that the result was inconclusive rather than strongly supportive of the null.
The overall percentage of cocaine-negative urine samples did not differ between groups from the beginning of induction through the end of intervention (weeks 13-26) (aripiprazole, M = 54%, SEM = 11%; placebo, M = 51%, SEM = 12%, P = 0.89). We did not calculate a Bayes factor because we had not specifically hypothesized a difference.
Self-reported cocaine craving (ecological momentary assessment)
During the aripiprazole/placebo intervention phase, when assessed at random moments in daily life by EMA, participants in the aripiprazole group reported cocaine craving ('yes??' or 'YES!!') at least as frequently as those in the placebo group (adjusted percentages from Glimmix model: 1.89% of prompts, 95% CI = 1.32-2.70, vs. 1.16% of prompts, 95% CI = 1.32-1.92, F(1,13) = 2.91, P = 0.11, r effect = 0.43, 95% CI = − 0.08 − 0.76) (Fig. 5) . Most participants in the placebo group never reported craving during the intervention phase; almost all participants in the aripiprazole group reported craving at least once (Fisher's exact P for group difference in 'never' vs. Relapse results were similar in the intent-to-treat (ITT) sample (P = 0.14). CI, confidence interval; HR, hazard ratio.
'ever' reported craving = 0.026) (Fig. 5 ). There did not appear to be a relationship between dose and incidence of craving. Both the participant with the greatest percentage of craving reports (7.6% of random prompts) and the participant who did not report any craving received the 5 mg dose for the majority of the intervention phase.
These findings did not change appreciably when we controlled for the group difference in years of heroin use (data not shown).
Self-reported mood (ecological momentary assessment)
During the aripiprazole/placebo intervention phase, participants in the aripiprazole group provided lower ratings of sadness, annoyance, boredom, relaxation, excitement, and stress than those in the placebo group [sadness, F(1,13) = 6.28, P < 0.05; annoyance, F(1,13) = 24.4, P < 0.0005; boredom, F(1,13) = 17.15, P < 0.005; relaxation, F(1,13) = 27.0, P < 0.0005; excitement, F(1,13) = 7.33, P < 0.05; stress, F(1,13) = 13.86, P < 0.005]. Ratings of tension, tiredness, and happiness did not differ between groups.
Adverse events
Of the expected adverse effects of aripiprazole, the one most commonly reported (in three participants) was agitation/restlessness. One of the three participants reporting agitation/restlessness (who tested positive for cocaine throughout the study) had aripiprazole dosing discontinued after 1 week of the 15 mg dose. For the other two, the symptoms resolved when the dosage was reduced from 15 to 5 mg. Three of the other aripiprazole participants were administered dose decreases to 5 mg because of reports of tremor (n = 1), paresthesia (n = 1), or suicidal ideation (n = 1). In the placebo group, one participant requested a dose decrease because of irritability. Another participant in the placebo group reported muscle spasms, which resolved within a week; the participant did not request a dose decrease. There was no significant difference between treatment groups in the number of adverse events or in the number of participants who reported any adverse events or any serious adverse events.
Discussion
This study raises two interesting issues -one issue arising from the results and the other issue arising from an unexpected difficulty in implementation.
The first issue is related to a possible paradox in the effects of aripiprazole. Although we cannot conclude that aripiprazole protected against cocaine lapse or relapse (in fact, most of our participants lapsed during the first 16 weeks after randomization), the survival curves (Figs 3 and 4) suggest that it did. The Bayes factors that we calculated for these measures do not allow us to rule out a beneficial effect. Allowing, for the moment, that aripiprazole may have increased the latency to lapse or relapse, any inference of benefit is complicated by our EMA data on cocaine craving. Participants randomized to aripiprazole reported cocaine craving at least as frequently as those randomized to placebo. The absolute rates of craving were low in both groups (1.87 vs. 1.01% of random prompts), and the difference did not reach statistical significance, but the effect size was large (equivalent to a Cohen's d of 0.95) and there was a significant difference across groups in the proportion of participants who never reported craving (Fig. 5) .
If we had simply found that aripiprazole exacerbated cocaine craving and use, we could liken it to the increase in ongoing amphetamine misuse that was observed in a previous human study (Tiihonen et al., 2007) . If we had found an increase in use with no increase in craving, we could liken it to the results of a previous human laboratory study in which cocaine self-administration (but not craving) increased as a seemingly compensatory response to blunting of cocaine's acute affects (Haney et al., 2011) . We found, instead, a tendency toward an increase in craving, accompanied by either no increase in lapse or relapse or, possibly, a protective effect against lapse and relapse. This combination of effects raises questions about the dissociability of daily-life craving from use. It also raises the question of whether a medication with this behavioral profile would be clinically acceptable. In our sample, no participants spontaneously reported that aripiprazole was exacerbating their craving for cocaine -but because we had not expected it to do so, we also did not probe for it. Cocaine craving in randomly prompted ecological momentary assessment entries was not reported frequently in either group, but tended to be reported more often in the aripiprazole group, F(1,13) = 2.91, P = 0.11, r effect = 0.43, 95% confidence interval = − 0.08 − 0.76. Almost all participants in the aripiprazole group reported craving at least once (Fisher's exact P for group difference in 'never' vs. 'ever' reported craving = 0.026).
It is conceivable that, given its partial-agonist activity at D 2 receptors, aripiprazole could prime stimulant craving. However, there is no indication that the subjective effects of aripiprazole are stimulant like (Lile et al., 2005; Stoops et al., 2006 Stoops et al., , 2013 Haney et al., 2011) . In humans trained to discriminate amphetamine or methamphetamine from placebo, aripiprazole was consistently identified as placebo (Lile et al., 2005; Sevak et al., 2011) .
The ambiguities in our results are largely because of the small size of the sample size -and this brings us to the second issue. We had much more difficulty than we expected in helping cocaine-using methadonemaintenance patients stop using cocaine for 2 weeks, even with voucher-based contingency management. In our identically designed study that targeted opiate relapse rather than cocaine relapse (Kowalczyk et al., 2015) , enrollees achieved initial opiate abstinence at such a high rate during a pilot study that we shortened the baseline from 10 to 4 weeks before running the full study. In the current study, we had the opposite experience: after a pilot study, we lengthened the baseline from 4 to 10 weeks, but we still could not randomize most of our enrollees to a relapse-prevention group. It is not surprising that cocaine abstinence was more of a challenge than opiate abstinence during methadone maintenance -but we did not anticipate the size of the challenge. We have not been alone in making statements such as: 'it is usually much easier to stop using cocaine than it is to stay permanently stopped. The challenge during this stage is…to avoid relapse' (Washton and Stone-Washton, 1993) . We must now conclude that even though relapse prevention is exceedingly important and even though clinical trials need to be designed specifically to examine it, we cannot assume that initial cessation of cocaine use is only a small hurdle. In nonresearch settings, where inpatient stays are not widely available and where the most effective forms of contingency management are rarely used, a medication that primarily acts to prevent relapse to cocaine use is unlikely to be a good standalone treatment.
In our sample, participants who achieved the abstinence criterion for randomization tended to be older and more educated (although they also had lower incomes) than those who did not. These factors may be important to keep in mind in recruiting participants for future clinical trials using relapse-prevention designs.
Like our successful relapse-prevention trial with clonidine as an adjunct to buprenorphine (Kowalczyk et al., 2015) , we designed the current trial to translate findings from the rat reinstatement model of relapse (Davies et al., 2004; Feltenstein et al., 2007 Feltenstein et al., , 2009 ). Our results with aripiprazole cannot be taken as clear evidence for the predictive validity of the reinstatement model, but crossspecies comparison is stymied by the seeming dissociation that we found between craving and use, which has no parallel in the reinstatement procedure. It might be possible to speculate on drug-specific mechanisms for our findings' having diverged from the predictions of the reinstatement model (e.g. complexities arising from the partial-agonist actions of aripiprazole), but we have no data related to that. Also, because of our small sample size, we cannot delve into our EMA data to address mechanistic questions at the behavioral level, as we did with our clonidine study (Kowalczyk et al., 2015) -for example, we do not have enough EMA data to examine craving as a function of the presence of cocainerelated cues.
Our EMA data did show that participants randomized to aripiprazole tended to rate both positive and negative moods lower than participants randomized to placebo, especially when we included EMA data from the postaripiprazole maintenance phase. This might reflect long-term mood-stabilizing effects of aripiprazole (Rybakowski, 2008) .
In summary, the present results suggest that in former cocaine users who have achieved abstinence, aripiprazole may slightly increase daily-life cocaine craving, but are inconclusive on its effect on lapse or relapse. Clarification of these unexpected findings will require additional relapse-prevention trials that are not hampered by low rates of initial abstinence from cocaine.
relevant previous result from our clonidine study) was 0.63, indicating that the result was inconclusive rather than strongly supportive of the null hypothesis.
The overall percentage of cocaine-negative urine samples did not differ between groups from the beginning of induction through the end of intervention (weeks 13-26) (aripiprazole, n = 9, M = 48%, SEM = 12%; placebo, n = 9, M = 55%, SEM = 11%, P = 0.66). We did not calculate a Bayes factor because we had not specifically hypothesized a difference.
Self-reported cocaine craving (ecological momentary assessment)
During the aripiprazole/placebo intervention phase, when assessed at random moments in daily life by EMA, participants in the aripiprazole group (n = 9) reported cocaine craving ('yes??' or 'YES!!') more frequently (adjusted percentages from Glimmix model: 3.01% of prompts, 95% CI = 2.29-3.95) than those in the placebo group (n = 8; 0.93% of prompts, 95% CI = 0.53-1.63) [F(1,14) = 18.28, P < 0.001, r effect = 0.75, 95% CI = 0.42-0.90]. This difference was partly driven by the presence of one or two especially frequent cravers in the aripiprazole group, but it did not disappear when the three highest cravers (readily discernible in Fig. A1) were excluded from the analysis, F(1,11) = 2.34, P = 0.15, r effect = 0.42, 95% CI = − 0.24-0.81 (the P value was no longer below 0.05, but the CI remained mostly above 0).
The greater frequency of craving in the aripiprazole group began to dissipate after discontinuation of aripiprazole: when the intervention and post-aripiprazole maintenance phases were analyzed together, the group difference was smaller: 2.76% (95% CI = 2.06-3.68) versus 1.92% (95% CI = 1.32-2.77%), F(1,14) = 3.38, P = 0.09, r effect = 0.44, 95% CI = − 0.05-0.76. One participant in the nonrandomized group used prescription opiates orally. In the intent-to-treat sample, participants in the aripiprazole group (n = 9) reported cocaine craving ("yes??" or "YES!!") more frequently (adjusted percentages from Glimmix model: 3.01% of prompts, 95% CI = 2.29-3.95%) than those in the placebo group (n = 8; 0.93% of prompts, 95% CI = 0.53-1.63%).
Self-reported mood (ecological momentary assessment)
During the aripiprazole/placebo intervention phase, participants in the aripiprazole group (n = 9) provided lower ratings of annoyance, boredom, and relaxation than those in the placebo group [n = 8; annoyed: F(1,14) = 6.78, P < 0.05; bored: F(1,14) = 5.41, P < 0.05; relaxed, F(1,14) = 33.81, P < 0.001]. Ratings of stress, sadness, tension, tiredness, excitement, and happiness did not differ significantly between groups.
